Loading clinical trials...
Loading clinical trials...
Understanding the 'Wearing Off' Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians
Conditions
Interventions
ocrelizumab
natalizumab
+1 more
Locations
1
Switzerland
Novartis Investigative Site
Basel, Switzerland
Start Date
January 10, 2023
Primary Completion Date
April 20, 2023
Completion Date
April 20, 2023
Last Updated
June 1, 2023
NCT06276634
NCT07225504
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions